In vitro activity of aminosterols against yeasts involved in blood stream infections

被引:8
作者
Alhanout, Kamel [1 ]
Djouhri, Lamia [1 ]
Vidal, Nicolas [2 ]
Brunel, Jean Michel [1 ]
Piarroux, Renaud [3 ]
Ranque, Stephane [1 ,3 ]
机构
[1] CNRS IRD, URMITE UMR 6236, Fac Med & Pharm, Marseille, France
[2] Univ Paul Cezanne, UPCAM iSm2, Case 342, Marseille, France
[3] AP HM Timone, Lab Parasitol Mycol, F-13385 Marseille 5, France
关键词
squalamine; antifungal; resistance; therapy; CANDIDA-SPP; ANTIMICROBIAL ACTIVITIES; SQUALAMINE; RESISTANCE;
D O I
10.3109/13693786.2010.502189
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Squalamine and other aminosterols have demonstrated interesting antimicrobial activities against clinical bacterial isolates and a limited number of reference yeast strains. We aimed to test whether squalamine and a synthetic aminosterol derivative (ASD) display any in vitro activity comparable to currently available systemic antifungals, an acceptable safety index, as well as to provide insights into their mechanism of action. The minimum inhibitory concentrations (MICs) of squalamine, ASD and available antifungals were determined against 21 yeast isolates that were recovered from cases of fungemia. Remarkably, homogeneous MICs ranging from 8-16 mg/L and from 1-2 mg/L were noted for squalamine and ASD, respectively, as opposes the heterogenous in vitro activity of available systemic antifungals. Aminosterols induced haemolysis, a surrogate for toxic effects to mammalian cells, at concentrations high above their MICs. In time-kill studies, killing was as fast with ASD as with amphotericin B. Both aminosterols induced a time-dependent disruption of yeast membrane, as evidenced by gradual increase of ATP efflux. In conclusion, our preliminary data indicate that aminosterols have the potential to be further developed as antifungals. Additional work is warranted to assess their toxicity and activity in experimental models.
引用
收藏
页码:121 / 125
页数:5
相关论文
共 18 条
  • [1] In vitro antibacterial activity of aminosterols against multidrug-resistant bacteria from patients with cystic fibrosis
    Alhanout, Kamel
    Brunel, Jean-Michel
    Raoult, Didier
    Rolain, Jean-Marc
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 64 (04) : 810 - 814
  • [2] Squalamine: A polyvalent drug of the future?
    Brunel, JM
    Salmi, C
    Loncle, C
    Vidal, N
    Letourneux, Y
    [J]. CURRENT CANCER DRUG TARGETS, 2005, 5 (04) : 267 - 272
  • [3] Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa
    Chin, Judy N.
    Jones, Ronald N.
    Sader, Helio S.
    Savage, Paul B.
    Rybak, Michael J.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 61 (02) : 365 - 370
  • [4] Treatment of invasive candidiasis in immunocompromised pediatric patients
    Fisher B.T.
    Zaoutis T.E.
    [J]. Pediatric Drugs, 2008, 10 (5) : 281 - 298
  • [5] Herbst RS, 2003, CLIN CANCER RES, V9, P4108
  • [6] Izgü F, 2007, MICROBIOL IMMUNOL, V51, P797, DOI 10.1111/j.1348-0421.2007.tb03975.x
  • [7] Antimicrobial activities of squalamine mimics
    Kikuchi, K
    Bernard, EM
    Sadownik, A
    Regen, SL
    Armstrong, D
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (07) : 1433 - 1438
  • [8] Candida resistance and its clinical relevance
    Klepser, Michael E.
    [J]. PHARMACOTHERAPY, 2006, 26 (06): : 68S - 75S
  • [9] Non-albicans Candida spp. causing fungaemia:: pathogenicity and antifungal resistance
    Krcmery, V
    Barnes, AJ
    [J]. JOURNAL OF HOSPITAL INFECTION, 2002, 50 (04) : 243 - 260
  • [10] Bactericidal activities of the cationic steroid CSA-13 and the cathelicidin peptide LL-37 against Helicobacter pylori in simulated gastric juice
    Leszczynska, Katarzyna
    Namiot, Andrzej
    Fein, David E.
    Wen, Qi
    Namiot, Zbigniew
    Savage, Paul B.
    Diamond, Scott
    Janmey, Paul A.
    Bucki, Robert
    [J]. BMC MICROBIOLOGY, 2009, 9